AHCO - AdaptHealth up 1.5% guides FY revenue above consensus
-
AdaptHealth ( NASDAQ: AHCO ) expects FY 2023 net revenue of $3.21B-3.29B; Adjusted EBITDA of $690M-750M; and total capital expenditures are expected to be 9-11% of net revenue.
-
For the FY 2022, net revenue expected to be near the midpoint of the previously-provided guidance range of $2.95B-3.01B ( vs. consensus of $2.98B ) and Adjusted EBITDA to be near the low end of the previously-provided guidance range of $620M-650M.
-
Steve Griggs, CEO, commented, “We are pleased with our guidance for the full year ending December 31, 2023 which reflects continued improvement and stabilization of the supply of PAP devices for our sleep business and overall non-acquired net revenue growth for the Company in the range of 8% to 10%.”
-
Stock up 1.5% post-market hours.
For further details see:
AdaptHealth up 1.5%, guides FY revenue above consensus